Pivot and Imperagen Secure $46M in Latest Startup Capital Infusion

The venture capital landscape is showing renewed focus on high-utility AI applications, as evidenced by two significant funding rounds this week. Pivot, a Paris-based startup, successfully closed a, 34.4 million Series B round led by Forestay Capital and Notion Capital. The company is building an AI operating system specifically for enterprise procurement, a sector traditionally burdened by manual workflows and fragmented data. By deploying agentic AI, Pivot aims to automate complex supply chain interactions, potentially reducing overhead costs for large-scale industrial clients. This capital injection brings the firm's total funding to, 60.2 million, signaling strong institutional confidence in the scalability of AI-driven procurement solutions. Simultaneously, the biotech sector continues to attract specialized capital, with Imperagen raising £5 million in a seed round led by PXN Ventures. The company is integrating quantum physics and artificial intelligence to redefine enzyme engineering. This intersection of computational biology and quantum modeling represents a growing trend where startups attempt to solve complex chemical problems that were previously computationally prohibitive. The participation of IQ Capital and Northern Gritstone in this round underscores the strategic interest in deep-tech solutions that could eventually disrupt traditional pharmaceutical and industrial manufacturing processes. For investors and market observers, these developments serve as a barometer for the current state of private equity. While the broader venture market remains selective, capital is clearly flowing toward companies that demonstrate tangible operational efficiency or scientific breakthroughs. The focus on agentic AI for enterprise procurement suggests that the next phase of corporate software adoption will prioritize autonomous agents over simple workflow automation. Meanwhile, the investment in Imperagen highlights the ongoing convergence of physical sciences and machine learning. Over the next week, market participants should monitor whether these funding patterns trigger further consolidation or competitive investment in the procurement tech and biotech spaces. As these companies move to deploy their new capital, their ability to deliver measurable ROI will likely determine the valuation trajectory for similar startups in the coming quarters. Investors should observe if these specific sub-sectors see an uptick in M&A activity or further venture interest as these technologies move from development toward broader commercial implementation.